The Carlyle Group acquires majority stake in TriNetX

Investment will accelerate development of new clinical research capabilities for healthcare organizations and life sciences customers

Register for free to listen to this article
Listen with Speechify
NEW YORK & CAMBRIDGE, Mass.—TriNetX announced today that global investment firm The Carlyle Group has made a strategic growth investment and will acquire a majority stake in TriNetX. Equity capital for the investment came from Carlyle Partners VII, an $18.5 billion fund which makes both majority and strategic minority investments, primarily in the U.S. Further terms of the transaction were not disclosed. 
“Our goal is to be on the desktop of every healthcare researcher in the world,” said Gadi Lachman, CEO of TriNetX. “To accomplish this we need to continue to develop solutions to support clinical research at our healthcare organizations and bring more global data and technologies such as AI, machine learning and analytics to researchers so that they can ask more questions and generate more real-world evidence. Carlyle’s investment accelerates our growth plans and will shorten the time it takes to turn our vision into reality.”
TriNetX provides web-based, on-demand access to harmonized global electronic health record (EHR) and claims data with a suite of highly intuitive analytics. The company notes that TriNetX is utilized in all parts of the drug development cycle, including protocol design and feasibility, site selection and patient identification for clinical trials. The company also uses clinical research for drugs already in the market to help researchers understand efficacy, risks and other market dynamics — and to generate real-world evidence to support hypothesis and decision making in real-time.
The longitudinal clinical and claims data available through TriNetX, which represents over 400 million patients, is mapped to controlled terminology. It consists of clinical facts from hundreds of healthcare organizations around the world, deep specialty data for all therapeutic areas — including COVID-19, cardiovascular, oncology, and rare disease — and linked medical claims, pharmacy claims and EHR data.
“With a deep clinical focus and a highly scalable data strategy, we believe TriNetX is well positioned for continued organic and inorganic growth opportunities. We’re excited to partner with Gadi and the TriNetX management team to help expand their global footprint and continue investing in the company’s mission to advance the collective understanding of human health,” noted Joe Bress, a Principal specializing in healthcare at The Carlyle Group.
Since its founding in 2013, TriNetX has built a global network of research hospitals, academic institutions, top biotech and pharmaceutical companies, contract research organizations and other specialty data partners. TriNetX is powered by a network of 170 healthcare organizations in 30 countries, and used by more than 40 life sciences organizations — including 15 of the world’s top 20 pharmaceutical companies.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue